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ABSTRACT
A newborn boy was diagnosed with CAH via the 2010 implemented NSP in Bulgaria. The 17-OH-progester-
one (17-OHP) from the 1st filter paper card (FPC) was 44.6 nmol/l, from the 2nd FPC 80 nmol/l. The exami-
nation on day 15th revealed as “only” sign slight hyperpigmentation of the scrotum. The screening suspicion 
“classical CAH” was confirmed by the increased serum levels of 17-OHP (normal electrolytes) and treatment 
with  hydrocortisone was started. The MLPA analysis revealed a hemizygous del3-4, c.622T>A; p.I173N. 
Family history: 2nd son of relatively short parents – mother’s height – 152 cm (SDSh = -2.12), father’s height – 
164 cm (SDSh= -1.96), MPH- 158 cm, SDS MPH= -2.54. The height of his older brother is 157 cm (SDSh= -3.01), 
while his target height of 164.5 cm (SDSh= -1.88) was markedly above the actual height. At 7 years he had 
initial pubarche and was the tallest boy in his class. He was taller than the average for his age until 12 years 
then he stopped growing. The older boy was also brought to a pediatric endocrinologist at 17 years of age. 
Elevated levels of 17-OHP in the serum >60 nmol/l (157.4) and on FPC:>285 nmol/l (537), together with the 
genetically verified CAH in the younger brother lead to the diagnosis “simple virilizing 21 OHD”, so treat-
ment with hydrocortisone was started. 
CONCLUSION: Some of the simple virilizing forms of CAH may remain unrecognized, esp. in “index-fam-
ilies”. The newly implemented CAH NSP represents a useful diagnostic tool also in such cases. Ultrasound of 
the adrenals and testes for testicular rest tumors is important initially and during follow up. 
Keywords: simple virilizing 21 OHD - CAH, screening, late diagnosis in males 
INTRODUCTION
Congenital adrenal hyperplasia results from au-
tosomal recessive inherited defects in cortisol biosyn-
thesis. More than 90% of cases are caused by 21-hy-
droxylase (21-OH) deficiency, found in 1:10 000 – 
1:15 000 live births worldwide. The measurement of 
17-OH progesterone (17-OHP) in dried blood spots 
worldwide showed its effectiveness in the early di-
agnostic of CAH caused by classic 21-OH deficien-
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cy. CAH is a disease suitable for newborn screening 
because it is common and potentially fatal. Early 
recognition and treatment can prevent morbidity 
and mortality, therefore universal screening for CAH 
is recommended by the ESPE and LWPES (15). In 
Bulgaria it was introduced in 2010 as part of the Na-
tional neonatal screening programs and the first re-
sults show a preliminary incidence 1:9266 (16). Data 
on CAH incidence beforehand were lacking. Some 
of the cases are familial, allowing to expect that the 
screening program could contribute for establishing 
the diagnosis in other family members as well. 
AIM
With the following case of a 17-year-old boy, 
diagnosed with simple virilizing CAH after the 
birth of an affected brother, we would like to draw 
attention to the missed opportunities for early 
recognition of the disease, the negative impact of the 
late diagnosis on the final height, the prevention of 
further complications and the problems of transition 
to the internal medicine endocrinologists. 
CASE PRESENTATIONS
Patient 1 (T.J.G.) was born in 1995 from a first 
uneventful pregnancy of healthy parents through 
Caesarian section because of coiled cord. His birth 
weight – 3500 g and birth length – 50 cm were on the 
50th percentile. The postnatal period was normal, ex-
cept for prolonged jaundice. 
The family history was unremarkable, but the 
parents were relatively short: mother’s height- 152 cm 
(SDSh = -2.12), father’s height- 164 cm (SDSh= -1.96), 
midparental height (MPH)-158 cm, SDS MPH= -2.54, 
target height is 164.5 cm (SDSh= -1.88). 
Growth and development: 
He was a healthy boy, with normal psychologi-
cal development. His growth up to 2 years of age was 
within the normal range (see Fig. 3), but the height 
velocity sharply increased after the second year (see 
Fig. 1 - Growth velocity of T.J.G.) At 7 years he was 
the tallest boy in his class with initial pubarche and 
mutation of the voice (see Fig. 2 - Growth curve of T. 
Fig. 1. Growth velocity of T.J.G. Fig. 2. Growth curve of T.J.G. from 1 to 17 years
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J. G. from 1-17 years). At eleven significant pubarche 
and axillarche were noticeable. He grew rapidly until 
12 years of age, when moustaches appeared, then lin-
ear growth stopped. He had already reached his final 
height -158 см, SDSh= -3.01 (see Fig. 2- Growth curve 
of T.J.G. from 1 to 17 years).
Diagnosis: 
His younger brother (patient 2, D.J.G.) was born, 
when he was 17 years old. The baby was seemingly 
healthy, with birth weight - 3600 g and birth length 
- 50 cm (50th percentile), but pathologic results from 
the NSP were reported. The 17-OHP from the 1st fil-
ter paper card (FPC) was 44.6 nmol/l (ISNS reference 
range-20), from the 2nd FPC- 80 nmol/l and from the 
3rd-201.6 nmol/l. Because of the sharply increasing 
17-OHP, a consultation with a paediatric endocrinol-
ogist was accomplished on the 15th day, and revealed 
as “only” sign slight hyperpigmentation of the scro-
tum. The screening suspicion was confirmed by the 
increased serum levels of 17-OHP, while the electro-
lytes were normal: 17-OH Progesterone > 60 (120) 
nmol/L (6.1±2.4), Testosterone- 4.24 nmol/l (4-14 
nmol/l), Na- 133 mmol/l (136-145), K- 5.97 mmol/l 
(3.5-5.1), Glucose -3.9 mmol/l (3.5-5.5). Hydrocorti-
sone treatment was started from the 15th day. The di-
agnosis simple virilizing CAH was confirmed by a 
molecular genetic analysis. The multiplex ligand de-
pendent probe amplification (MLPA) and sequenc-
ing analysis revealed a hemizygous deletion 3-4 and 
a point mutation c.622T>A; p.I173N. Normal growth 
was observed during the first 18 months (see Fig. 4 - 
Growth curve of D. J. G. up to 1 1/2 years). 
The parents were informed in details about the 
course of the disease and the pitfalls of over- and un-
dertreatment. In the course of the interview, they 
shared their concern about the growth of their older 
son. The auxological data from his records were re-
quested and the older boy was also brought to a pedi-
atric endocrinologist several months later. He seemed 
clinically healthy, with athletic constitution. The X-
ray of the wrist showed fused epiphyses. Elevated lev-
els of 17-OHP in the serum > 60 nmol/l (157.4) and 
on FPC: > 285 nmol/l (537), together with the veri-
fied CAH in the younger brother lead to the diagno-
sis “simple virilizing 21 OHD”. At the time of diag-
nosis he had normal testosterone – 15 nmol/l. Sub-
stitution with hydrocortisone was started at 17 years 
of age with initial dosage- 20 mg / 24h. The diagno-
sis was a shock for the patient and his family. The 
boy had expectations that the treatment will promote 
his further growth and was frustrated about the poor 
height prognosis. This led to a bad compliance and 
at some point he stopped the treatment completely. 
An ultrasound of the adrenals and testes was car-
ried out shortly before his 18th birthday. No testicu-
lar adrenal rest tumors (TARTs) were detected. At 18 
years of age, according to the country legislation, his 
care should be transferred to an internal medicine 
endocrinologist. 
DISCUSSION 
The diagnosis of simple virilizing CAH in boys 
is a challenge, especially before the advent of the 
newborn screening programmes. Boys with classic 
CAH have no signs of the disease at birth, except 
subtle hyperpigmentation, as our patient 2, and 
possible penile enlargement. They may present with 
early virilization at age 2-4 years (9). 
Growth aspects
Until recently, it was generally perceived that 
children with CAH would ultimately be short as 
adults and invariably below their genetic potential. 
However, studies over the last ten years have 
contrasted this idea, suggesting that most children 
with CAH will have a final height (FH) below their 
target height but within 2 standard deviations (SD) 
of the mean (11).  Although this comparison is not 
very suitable for our patient 1, because of the low 
SDS of the TH, a variation of – 1.13 SDS between 
the TH and FH shows the deleterious effect of the 
very early growth spurt. Critically important time 
periods of growth in all children are infancy, early 
adolescence and puberty. Interestingly, the negative 
effect of androgen excess on growth and skeletal 
maturation seen in later childhood does not occur 
during infancy. A report from Sweden on the phys-
ical development in 15 children with no or insuffi-
cient treatment showed no growth acceleration or 
virilization until after 18 months of age (17). A study 
from the Netherlands on 17 children with untreated 
simple-virilizing CAH revealed no increased height 
velocity in the first 12 months of life (5). These obser-
vations indicate that growth during the first 1.5 years 
is not very sensitive to androgens (5,17) and that sub-
optimal control could be tolerated at that age regard-
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ing the final height (4). The early growth curves of 
our two patients, one of them treated early and the 
other untreated, are quite similar and are consistent 
with these data (see Fig. 3 - Growth curve of T.J.G up 
to 2 years and Fig. 4 - Growth curve of D.J.G up to 1 
½ years). 
Boys with simple virilizing CAH are more 
prone to impaired height, because, on one hand, they 
are more likely to be diagnosed late and on the other, 
they have increased sensibility to aromatized estro-
gens from adrenal androgens and this could contrib-
ute further to the early fusion of the growth plates 
(12). Sometimes the clinical signs are noticed, but 
not recognized as pathological. Such was the case 
of T.J.G, who had conspicuously accelerated growth 
and precocious pubarche. Unfortunately, neither of 
these signs was brought to a specialist’s attention. 
Puberty
The precocious pubarche can be defined as pu-
bic hair onset before the age of 8 in girls and 9 in 
boys. In most of the cases, it is related to nonpatho-
logical precocious secretion of adrenal androgens, 
but in 5-20 % the cause is non-classical congenital 
adrenal hyperplasia. It always necessitates overall 
clinical examination and assessment of the growth 
velocity and bone maturation. Many authors recom-
mend an ACTH test, while Armengaud et al. prefer a 
selective strategy, based on a basal 17-OHP level (2). 
In non-classical CAH, growth acceleration is small, 
but bone maturation is more pronounced (13). 
Delayed diagnosis in the boys with classical 
CAH is invariably associated with progressive viril-
ization (precocious pseudo-puberty), with marked-
ly advanced bone maturation. Chronically elevated 
adrenal androgens can lead to early maturation of 
the hypothalamo-pituitary-gonadotrphin axis (7). 
When advanced bone maturation has reached the 
average age of the onset of puberty, the latter be-
gins. In other circumstances, the hypothalamo-pitu-
itary axis may be down-regulated by high levels of 
testosterone produced by the peripheral metabolism 
of the adrenal precursors. When treatment is start-
ed, testosterone is suppressed, thus the feedback loop 
Fig. 3. Growth curve of T.J.G up to 2 years
Fig. 4. Growth curve of D.J.G up to 1 ½ years
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opens and central puberty starts (6). Unfortunate-
ly we lack reliable data on the pubertal development 
in our patient, except the precocious pubarche. The 
very early maturation permits speculations whether 
the androgen excess is the only culprit for the short 
adult height, but the small peak at his growth veloc-
ity curve between 10 and 11 years of age probably re-
flects his blunted pubertal growth spurt, occurring 
at the physiological age. 
Complications and treatment of CAH in adult 
life
CAH is a life-long chronic disorder. In 
childhood, treatment is focused on issues of gender 
assignment and optimization of growth and pubertal 
development. Priorities change with increasing age, 
typically focusing on fertility in early adult life and 
prevention of metabolic syndrome and osteoporosis 
in middle and older age (1). The reduced fertility in 
men is associated mainly with TARTs or sometimes 
with suppressed gonadotrophin secretion due to ad-
renal androgen excess (14). TARTs can be detected 
from childhood in boys with inadequately controlled 
classical CAH (8). They are ACTH dependent, and 
their growth can be reversed by suppressive gluco-
corticoid treatment.  They originate from adreno-
cortical remnants in the testes. TARTs are of special 
concern in our patient, because of the long standing 
ACTH stimulation. 
There is still no consensus for management of 
adults with CAH. Probably this will soon be changed 
because the number of patients is increasing. With the 
glucocorticoid treatment and the newborn screening 
programmes, the majority of children with 21-hy-
droxylase deficiency are reaching adulthood (3). For 
adults, clinicians may use hydrocortisone, predni-
sone, prednisolone, dexamethasone, or a combina-
tion of treatments. Practice varies worldwide. An UK 
survey of 30 teaching centers, showed a variety of dif-
ferent regimens to treat CAH adults; hydrocortisone 
was the most common, followed by dexamethasone 
and then prednisolone. Sixty percent of practitioners 
used a reverse circadian pattern of glucocorticoid ad-
ministration. Patient-related factors often determine 
the specific regimen (10). New preparations with fast 
and delayed hydrocortisone release are developed.
CONCLUSIONS
Some of the simple virilising forms of CAH may 
remain unrecognized, especially in “index-families”. 
The newly implemented CAH NSP represents a 
useful diagnostic tool also in such cases. Initially 
and during follow up ultrasound of the adrenals and 
testes for testicular rest tumors is important. 
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